These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
232 related articles for article (PubMed ID: 8033099)
1. Preclinical antitumor activity of temozolomide in mice: efficacy against human brain tumor xenografts and synergism with 1,3-bis(2-chloroethyl)-1-nitrosourea. Plowman J; Waud WR; Koutsoukos AD; Rubinstein LV; Moore TD; Grever MR Cancer Res; 1994 Jul; 54(14):3793-9. PubMed ID: 8033099 [TBL] [Abstract][Full Text] [Related]
2. Effect of temozolomide and dacarbazine on O6-alkylguanine-DNA alkyltransferase activity and sensitivity of human tumor cells and xenografts to 1,3-bis(2-chloroethyl)-1-nitrosourea. Mitchell RB; Dolan ME Cancer Chemother Pharmacol; 1993; 32(1):59-63. PubMed ID: 8462125 [TBL] [Abstract][Full Text] [Related]
3. Thresholds of O6-alkylguanine-DNA alkyltransferase which confer significant resistance of human glial tumor xenografts to treatment with 1,3-bis(2-chloroethyl)-1-nitrosourea or temozolomide. Kokkinakis DM; Bocangel DB; Schold SC; Moschel RC; Pegg AE Clin Cancer Res; 2001 Feb; 7(2):421-8. PubMed ID: 11234899 [TBL] [Abstract][Full Text] [Related]
4. Synergy between methionine stress and chemotherapy in the treatment of brain tumor xenografts in athymic mice. Kokkinakis DM; Hoffman RM; Frenkel EP; Wick JB; Han Q; Xu M; Tan Y; Schold SC Cancer Res; 2001 May; 61(10):4017-23. PubMed ID: 11358820 [TBL] [Abstract][Full Text] [Related]
5. O6-benzylguanine enhances the sensitivity of a glioma xenograft with low O6-alkylguanine-DNA alkyltransferase activity to temozolomide and BCNU. Wedge SR; Newlands ES Br J Cancer; 1996 May; 73(9):1049-52. PubMed ID: 8624262 [TBL] [Abstract][Full Text] [Related]
6. Treatment of subcutaneous and intracranial brain tumor xenografts with O6-benzylguanine and 1,3-bis(2-chloroethyl)-1-nitrosourea. Felker GM; Friedman HS; Dolan ME; Moschel RC; Schold C Cancer Chemother Pharmacol; 1993; 32(6):471-6. PubMed ID: 8258196 [TBL] [Abstract][Full Text] [Related]
7. 2-Chloroethyl-3-sarcosinamide-1-nitrosourea, a novel chloroethylnitrosourea analogue with enhanced antitumor activity against human glioma xenografts. Marcantonio D; Panasci LC; Hollingshead MG; Alley MC; Camalier RF; Sausville EA; Dykes DJ; Carter CA; Malspeis L Cancer Res; 1997 Sep; 57(18):3895-8. PubMed ID: 9307267 [TBL] [Abstract][Full Text] [Related]
8. Activity of temozolomide in the treatment of central nervous system tumor xenografts. Friedman HS; Dolan ME; Pegg AE; Marcelli S; Keir S; Catino JJ; Bigner DD; Schold SC Cancer Res; 1995 Jul; 55(13):2853-7. PubMed ID: 7796412 [TBL] [Abstract][Full Text] [Related]
9. A phase I trial of 1,3-bis(2-chloroethyl)-1-nitrosourea plus temozolomide: a North American Brain Tumor Consortium study. Schold SC; Kuhn JG; Chang SM; Bosik ME; Robins HI; Mehta MP; Spence AM; Fulton D; Fink KL; Prados MD Neuro Oncol; 2000 Jan; 2(1):34-9. PubMed ID: 11302252 [TBL] [Abstract][Full Text] [Related]
10. Treatment of human brain tumor xenografts with O6-benzyl-2'-deoxyguanosine and BCNU. Schold SC; Kokkinakis DM; Rudy JL; Moschel RC; Pegg AE Cancer Res; 1996 May; 56(9):2076-81. PubMed ID: 8616853 [TBL] [Abstract][Full Text] [Related]
11. Eradication of human medulloblastoma tumor xenografts with a combination of O6-benzyl-2'-deoxyguanosine and 1,3-bis(2-chloroethyl)1-nitrosourea. Kokkinakis DM; Moschel RC; Pegg AE; Schold SC Clin Cancer Res; 1999 Nov; 5(11):3676-81. PubMed ID: 10589786 [TBL] [Abstract][Full Text] [Related]
12. Effect of single and multiple administration of an O6-benzylguanine/temozolomide combination: an evaluation in a human melanoma xenograft model. Wedge SR; Porteous JK; Newlands ES Cancer Chemother Pharmacol; 1997; 40(3):266-72. PubMed ID: 9219512 [TBL] [Abstract][Full Text] [Related]
13. A randomized phase I and pharmacological trial of sequences of 1,3-bis(2-chloroethyl)-1-nitrosourea and temozolomide in patients with advanced solid neoplasms. Hammond LA; Eckardt JR; Kuhn JG; Gerson SL; Johnson T; Smith L; Drengler RL; Campbell E; Weiss GR; Von Hoff DD; Rowinsky EK Clin Cancer Res; 2004 Mar; 10(5):1645-56. PubMed ID: 15014015 [TBL] [Abstract][Full Text] [Related]
14. Potentiation of temozolomide and BCNU cytotoxicity by O(6)-benzylguanine: a comparative study in vitro. Wedge SR; Porteus JK; May BL; Newlands ES Br J Cancer; 1996 Feb; 73(4):482-90. PubMed ID: 8595163 [TBL] [Abstract][Full Text] [Related]
15. Phase 1 study of 28-day, low-dose temozolomide and BCNU in the treatment of malignant gliomas after radiation therapy. Raizer JJ; Malkin MG; Kleber M; Abrey LE Neuro Oncol; 2004 Jul; 6(3):247-52. PubMed ID: 15279717 [TBL] [Abstract][Full Text] [Related]
17. Blockage of abasic site repair enhances antitumor efficacy of 1,3-bis-(2-chloroethyl)-1-nitrosourea in colon tumor xenografts. Liu L; Yan L; Donze JR; Gerson SL Mol Cancer Ther; 2003 Oct; 2(10):1061-6. PubMed ID: 14578471 [TBL] [Abstract][Full Text] [Related]
18. Antitumor activity of temozolomide combined with irinotecan is partly independent of O6-methylguanine-DNA methyltransferase and mismatch repair phenotypes in xenograft models. Houghton PJ; Stewart CF; Cheshire PJ; Richmond LB; Kirstein MN; Poquette CA; Tan M; Friedman HS; Brent TP Clin Cancer Res; 2000 Oct; 6(10):4110-8. PubMed ID: 11051264 [TBL] [Abstract][Full Text] [Related]
19. Anti-neoplastic activity of sequenced administration of O6-benzylguanine, streptozotocin, and 1,3-bis(2-chloroethyl)-1-nitrosourea in vitro and in vivo. Marathi UK; Dolan ME; Erickson LC Biochem Pharmacol; 1994 Nov; 48(11):2127-34. PubMed ID: 7802703 [TBL] [Abstract][Full Text] [Related]
20. Potentiation of BCNU antitumor efficacy by 9-substituted O6-benzylguanines. Effect of metabolism. Kokkinakis DM; Moschel RC; Pegg AE; Schold SC Cancer Chemother Pharmacol; 2000; 45(1):69-77. PubMed ID: 10647505 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]